Iovance Biotherapeutics, Inc 10-Q for FY2026 Q3
Iovance Biotherapeutics, Inc. (IOVA)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
Iovance Biotherapeutics, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Iovance reported product revenue increases of $54.0 million, or 80%, and $115.5 million, or 65%, for the three and nine months ended September 30, 2026. Net loss declined $69.0 million, or 76%, and $170.4 million, or 53%. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $121.47M
- up 80.1% from $67.46M a year earlier
- Net loss
- $22.27M
- compared with a net loss of $91.25M a year earlier
- Diluted EPS
- -$0.05
- compared with -$0.25 a year earlier